Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | GALR3 | O60755 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | GUSB | P08236 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | GLA | P06280 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20161984 | 0.83 | MEN1 (0.52) | HTTSMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL12605662 | 0.73 | HTT (0.61) | HTTSMN1; SMN2GALR3RAB9AOPRK1 | |
| SCHEMBL14754389 | 0.71 | CYP1A2 (0.70) | SMN1; SMN2KMT2AALDH1A1POLBKDM4E | |
| SCHEMBL5053541 | 0.71 | HTT (0.73) | HTTSMN1; SMN2GALR3RAB9AOPRK1 | |
| SCHEMBL20079722 | 0.71 | YTHDC1 (0.45) | HTTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL15075719 | 0.70 | SMN1; SMN2 (0.50) | HTTSMN1; SMN2GALR3RAB9AOPRK1 | |
| SCHEMBL8402836 | 0.70 | HTT (0.75) | HTTSMN1; SMN2GALR3RAB9AOPRK1 | |
| SCHEMBL19036473 | 0.69 | YTHDC1 (0.44) | HTTSMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL4872495 | 0.69 | HTT (0.73) | HTTSMN1; SMN2GALR3RAB9AOPRK1 | |
| SCHEMBL19308467 | 0.69 | HTT (0.73) | HTTSMN1; SMN2GALR3RAB9AOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | HTT 160/4885SMN1; SMN2 129/4885GALR3 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.